Delivery Order SPE2DB22D3301-SPE2DB26FX3WT
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Esbriet 267 mg tablets (270 count) under a firm fixed-price contract valued at $20,555.70, with an ultimate completion date of October 17, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of AmerisourceBergen's substantial role as a critical pharmaceutical distributor within the federal medical supply chain. The order will be...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Esbriet 801 mg tablets (90-count) with a completion date of October 6, 2025. This is a firm fixed price, non-set-aside contract performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Esbriet 267 mg tablets (270-count packages) at a firm fixed price of $3,425.95, with completion scheduled for September 30, 2025. This is a non-set-aside competitive award issued as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Esbriet 801 mg tablets (90-count units) with a contract ceiling value of $3,425.95. This non-set-aside, competitively awarded delivery order carries firm fixed pricing and is scheduled for completion by June 3, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Esbriet (pirfenidone) 801 mg tablets in a 90-count package. This competitively awarded, firm fixed price delivery order carries a ceiling value of $3,425.95 and is scheduled for completion by July 10, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside award, this delivery...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain for 270 tablets of Esbriet 267 mg on September 23, 2025, with a ceiling value of $6,851.90 and an ultimate completion date of October 15, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a delivery order valued at $3,425.95 to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of Esbriet 267 mg tablets (270-count). This is a firm fixed price, competitively awarded contract with no set-aside designation, scheduled for completion by November 19, 2025. The contract is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Esbriet (pirfenidone) 267 mg tablets in a quantity of 270 units. This non-set-aside, competitively awarded contract carries a firm fixed price structure with an ultimate completion date of October 8, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Esbriet (pirfenidone) 801 mg tablets in a 90-count quantity. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 13, 2025, and performance location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA, enabling the company...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. The contract, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, operates under a firm fixed price structure with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB26FX3WTDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Esbriet 267 mg tablets (270-count units) with a ceiling value of $10,277.85. This firm fixed-price delivery order, with an ultimate completion date of November 18, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, leverages its comprehensive pharmaceutical supply portfolio to support military and veteran healthcare systems through the DLA Medical Supply Chain. This award for Esbriet, a specialty pharmaceutical used in the treatment of idiopathic pulmonary fibrosis, exemplifies the contractor's capability to deliver brand-name medications across multiple therapeutic domains. The delivery order fulfills federal healthcare requirements while demonstrating the contractor's competitive position in providing specialized medical commodities to Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 10/27/25 |